Tesamorelin, sermorelin, and GHRH analogs: comparative endocrine review

Tesamorelin, sermorelin, and GHRH analogs: comparative endocrine review

Reviews in Endocrine and Metabolic Disorders

2024

Study summary

Comparative review of GHRH analogs and GH-axis therapeutics including tesamorelin and sermorelin.

Peptides studied

Stack studied

GH Optimization Stack

Key findings

Tesamorelin had the strongest modern clinical data, especially for visceral adiposity outcomes.

Study details

Study type

review article

Journal

Reviews in Endocrine and Metabolic Disorders

DOI / PubMed

10.1007/s11154-023-09780-9

Year

2024

Explore peptide profiles

Discover compounds, understand their mechanisms, and explore the research behind each peptide.

Explore the science. Follow the connections.

Start with a peptide, a goal, a mechanism, or a study. Discover how every piece of research connects across the platform.

Search peptides, goals, studies,...

Research made connected. Build for curious minds.

© 2026 All rights reserved

This platform is for informational and research purposes only. It does not provide medical advice. Always consult a qualified healthcare provider.

Explore the science. Follow the connections.

Start with a peptide, a goal, a mechanism, or a study. Discover how every piece of research connects across the platform.

Search peptides, goals, studies,...

Research made connected. Build for curious minds.

© 2026 All rights reserved

This platform is for informational and research purposes only. It does not provide medical advice. Always consult a qualified healthcare provider.

Explore the science. Follow the connections.

Start with a peptide, a goal, a mechanism, or a study. Discover how every piece of research connects across the platform.

Search peptides, goals, studies,...

Research made connected. Build for curious minds.

© 2026 All rights reserved

This platform is for informational and research purposes only. It does not provide medical advice. Always consult a qualified healthcare provider.